RTD Financial Advisors Inc. Invests $251,000 in Zoetis Inc. (NYSE:ZTS)

RTD Financial Advisors Inc. bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 1,285 shares of the company’s stock, valued at approximately $251,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Quarry LP increased its holdings in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the last quarter. LRI Investments LLC bought a new stake in Zoetis in the 1st quarter worth approximately $43,000. Fortitude Family Office LLC raised its holdings in shares of Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after acquiring an additional 222 shares in the last quarter. Central Valley Advisors LLC bought a new position in shares of Zoetis during the 2nd quarter valued at approximately $49,000. Finally, EdgeRock Capital LLC purchased a new stake in Zoetis during the second quarter valued at $56,000. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ZTS shares. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus increased their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Stock Up 0.7 %

Shares of ZTS traded up $1.16 during midday trading on Wednesday, hitting $176.43. 165,840 shares of the company’s stock traded hands, compared to its average volume of 2,504,797. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm’s fifty day moving average is $188.71 and its 200-day moving average is $179.23. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $79.93 billion, a price-to-earnings ratio of 33.16, a price-to-earnings-growth ratio of 2.68 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 52.59%. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the business earned $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.91 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s payout ratio is presently 32.33%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.